哌啶-1-羧酰胺氢溴酸 | 332367-56-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 哌啶-1-羧酰胺氢溴酸
• 英文名称: piperidine-1-carboximidamide hydrobromide
• 英文别名: piperidine-1-carboximidamide;hydrobromide
• CAS: 332367-56-3
• 化学式: BrH*C₆H₁₃N₃
• mdl: MFCD00829953
• 分子量: 208.101
• InChiKey: UOTPMDPAIHTZNH-UHFFFAOYSA-N

物化性质

• 熔点：
  129 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.15
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  53.1
• 氢给体数：
  3
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  哌啶-1-羧酰胺氢溴酸 、 5-oxo-1-(3-trifluoromethyl-pyridin-2-yl)-azepane-4-carboxylic acid ethyl ester 在 哌啶-1-羧酰胺氢溴酸 作用下， 以51的产率得到
  参考文献：
  名称：

  Tetrahydro-pyrimidoazepines as modulators of TRPV1

  摘要：

  本文描述了某些四氢嘧啶并氮杂环化合物，它们可作为TRPV1调节剂使用。这些化合物可用于制备药物组合物和治疗TRPV1介导的疾病状态、障碍和病况的方法。因此，这些化合物可用于治疗疼痛、瘙痒、咳嗽、哮喘或炎症性肠病等疾病。

  公开号：

  US20070225275A1
• 作为试剂：
  描述：

  哌啶-1-羧酰胺氢溴酸 、 5-oxo-1-(3-trifluoromethyl-pyridin-2-yl)-azepane-4-carboxylic acid ethyl ester 在 哌啶-1-羧酰胺氢溴酸 作用下， 以51的产率得到
  参考文献：
  名称：

  Tetrahydro-pyrimidoazepines as modulators of TRPV1

  摘要：

  本文描述了某些四氢嘧啶并氮杂环化合物，它们可作为TRPV1调节剂使用。这些化合物可用于制备药物组合物和治疗TRPV1介导的疾病状态、障碍和病况的方法。因此，这些化合物可用于治疗疼痛、瘙痒、咳嗽、哮喘或炎症性肠病等疾病。

  公开号：

  US20070225275A1

文献信息

• [EN] TETRAHYDROFURO[3,4-C]ISOQUINOLINES AS INHIBITORS OF PDE4<br/>[FR] TÉTRAHYDROFURO [3,4-C] ISOQUINOLINES EN TANT QU'INHIBITEURS DE PDE4
  申请人：TAKEDA GMBH

  公开号：WO2018069210A1

  公开（公告）日：2018-04-19

  The compounds of a certain formula 1, in which R1, R2 and R3 have the meanings as given in the description, are novel effective inhibitors of phosphodiesterase type 4.

  某一特定化学式1的化合物，其中R1、R2和R3的含义如描述中所述，是磷酸二酯酶4型的新型有效抑制剂。
• Amide Compound
  申请人：Matsumoto Takahiro

  公开号：US20080312226A1

  公开（公告）日：2008-12-18

  There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I 0 ): R 1 —C—R 2 —R 3 —R 4 (I 0 ) wherein Z is oxygen or sulfur; R 1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R 1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R 2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R 3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, —CO—, etc.; and R 4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

  提供了一种FAAH抑制剂和预防或治疗脑血管疾病或睡眠障碍的药物，其中预防或治疗剂包括化合物(I0)的一种：R1-C-R2-R3-R4(I0)，其中Z为氧或硫；R1为芳基，可以被取代，或者是可以被取代的杂环基；R1a为氢原子，可以被取代的碳氢基，羟基等；R2为可以被取代的哌啶-1,4-二基，或者可以被取代的哌嗪-1,4-二基；R3为从具有1到3个氮、氧和硫杂原子的5元芳香杂环基中消除两个氢原子形成的基团，可以进一步被取代，-CO-等；R4为可以被取代的碳氢基或者可以被取代的杂环基；或其盐。
• Amide compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07851473B2

  公开（公告）日：2010-12-14

  There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I0): wherein Z is oxygen or sulfur; R1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, —CO—, etc.; and R4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

  提供了一种FAAH抑制剂和用于预防或治疗脑血管疾病或睡眠障碍的预防性或治疗性制剂，它包括公式（I0）的化合物：其中Z是氧或硫；R1是取代的芳基或取代的杂环基；R1a是氢原子、可取代的碳氢基、羟基等；R2是可取代的哌啶-1,4-二基或可取代的哌嗪-1,4-二基；R3是由1至3个从氮、氧和硫中选择的杂原子构成的5-成员芳香杂环基消去两个氢原子形成的基团，它可以进一步取代，-CO-等；R4是可取代的碳氢基或可取代的杂环基；或其盐。
• TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1
  申请人：Janssen Pharmaceutica NV

  公开号：US20140135311A1

  公开（公告）日：2014-05-15

  Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.

  本文描述了某些四氢嘧啶并氮杂莫尔环化合物，它们可用作TRPV1调节剂。这些化合物可用于制备药物组合物和治疗TRPV1介导的疾病状态、障碍和情况的方法。因此，这些化合物可用于治疗疼痛、瘙痒、咳嗽、哮喘或炎症性肠病等疾病。
• AMIDE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1813606A1

  公开（公告）日：2007-08-01

  There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I0): wherein Z is oxygen or sulfur; R1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, -CO-, etc.; and R4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

  本发明提供了一种 FAAH 抑制剂和一种用于脑血管疾病或睡眠障碍的预防或治疗剂。该预防或治疗剂包括式（I0）化合物： 其中 Z 是氧或硫；R1 是可被取代的芳基或可被取代的杂环基团；R1a 是氢原子、可被取代的烃基、羟基等。R2 是可被取代的哌啶-1,4-二基或可被取代的哌嗪-1,4-二基；R3 是通过从具有 1 至 3 个选自氮、氧和硫的杂原子的 5 元芳香杂环基团中消除两个氢原子而形成的基团，该基团可被进一步取代、-CO- 等；以及 R4 是可被取代的烃基或可被取代的杂环基；或其盐。